Biotech's usual Q4 strength ahead of JPM season makes aggressive rallies in smaller names highly likely. ARKG is starting to break out, and PDS Biotechnology is showing multiple buy signals. If ARKG keeps running as expected, Nautilus Biotechnology, PDS Biotechnology and Quantum-Si could reasonably rally toward about $10 soon; broken chart structures would invalidate that view. x.com  x.com 

ARK Genomic Revolution ETF holds several of 2026's top-performing stocks as its biggest positions. The signal to take profits will be when CNBC features Cathie Wood on TV, likely within one to two months, since CNBC tends to ring the bell at the top. x.com 

Genomics and innovation biotech stocks are an unusually asymmetric short: the companies are 50-100% overvalued even on an aggressive DCF and burn cash while rates break out. They are benefiting from quarter-end markups that end tomorrow, the chart is overbought, and they broke out on Moderna news that has nothing to do with them. Some will benefit from AI, but that is largely narrative. x.com 

ARKG's genomics thesis faces a timing problem, as much of the index consists of companies with no important clinical data readouts until 2028 or later. Clinical trials remain painstakingly long, and AI is moving faster than trial progress can keep up with, raising the question of when the broader biotech theme becomes overextended. x.com 

Genomics stocks appear to be benefiting from AI, with the ARK Genomic Revolution ETF clearly outpacing broader biotech. x.com 

Biotech is the next AI trade after compute and memory as the market shifts to the application layer, and the ARK Genomic Revolution ETF could top $100. Biotech runs on data, pattern recognition, R&D and precise manufacturing, all things AI excels at, helping firms like Twist, Tempus and CRISPR make drugs faster and reach profit sooner. The Trump administration is also opening the door to innovation and M&A. Winners are hard to pick, so a basket is easiest; expect volatility. x.com  x.com  x.com  … Show more

ARK Innovation ETF is unlikely to ever regain its Covid highs relative to the Nasdaq 100. It just hit a fresh 52-week low against the Nasdaq 100 and is nearing an all-time relative low, while carrying one of the highest ETF expense ratios. Cathie Wood day-trades names in the fund and has badly underperformed the index for years while collecting hundreds of millions in fees. x.com 

Small caps should lead in the coming days, and high short interest in many names could fuel a short squeeze as shorts are forced to buy back. Names include Amprius, Lemonade, LightPath, Navitas, Ichor, Cohu, ACM Research, Aeva, Ouster, Ondas, BlackSky, Critical Metals, United States Antimony, Lightwave Logic, Arteris, Sidus Space, Satellogic and Babcock & Wilcox. x.com  x.com 

Collectar Biosciences is easy to short on all brokers, which gives it a better chance of being short squeezed, the setup that justifies buying rather than shorting it. x.com